Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
4
67%
Ph not_applicable
1
17%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
N/A1 (16.7%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
completednot_applicable

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

NCT02100371
terminatedphase_2

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

NCT01357655
completedphase_1

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

NCT00884546
completedphase_1

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

NCT01218477
completedphase_1

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

NCT00909402
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02100371Not Applicable

Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

Completed
NCT01357655Phase 2

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Terminated
NCT00884546Phase 1

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Completed
NCT01218477Phase 1

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Completed
NCT00909402Phase 1

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Completed
NCT00927875Phase 1

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6